Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
R

Ryvu Therapeutics SA
F:9Y4

Watchlist Manager
Ryvu Therapeutics SA
F:9Y4
Watchlist
Price: 4.035 EUR -1.94%
Market Cap: €93.3m
Write Note Create Alert Ask AI

Wall St Price Targets

9Y4 Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast 9Y4 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 9Y4 is 7.699 EUR with a low forecast of 5.326 EUR and a high forecast of 9.445 EUR.

9Y4 Lowest Forecast
Wall Street Target
€5.326
32% Upside
9Y4 Average Forecast
Wall Street Target
€7.699
91% Upside
9Y4 Highest Forecast
Wall Street Target
€9.445
134% Upside
Lowest Forecast
Price Target
5.326 EUR
32% Upside
Average Forecast
Price Target
7.699 EUR
91% Upside
Highest Forecast
Price Target
9.445 EUR
134% Upside
Ryvu Therapeutics SA Competitors:
Price Targets
MNPR
Monopar Therapeutics Inc
13% Upside
D
DREAMFOLKS
Dreamfolks Services Ltd
113% Upside
MNPR
Monopar Therapeutics Inc
13% Upside
D
DREAMFOLKS
Dreamfolks Services Ltd
113% Upside

Revenue
Forecast

14% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-32%
Average Miss
14% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-32%
Average Miss

Over the last 12 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 8 years is 22%.

What are analyst estimates?

Gross Profit
Forecast

23% / Year
Past Growth
-29% / Year
Estimated Growth
Estimates Accuracy
-57%
Average Miss
23% / Year
Past Growth
-29% / Year
Estimated Growth
Estimates Accuracy
-57%
Average Miss

Over the last 12 years, the compound annual growth rate for Gross Profit has been 23%. The projected CAGR for the next 3 years is -29%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

What are analyst estimates?

Continue 9Y4 Research

Summary
9Y4 intrinsic value, competitors valuation, and company profile.
DCF Valuation
9Y4 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
9Y4 stock valuation using valuation multiples.
Wall St Estimates
9Y4 price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
9Y4 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Ryvu Therapeutics SA listings:
WSE • PLN
RVU
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 9Y4's stock price target?
Price Target
7.699 EUR

According to Wall Street analysts, the average 1-year price target for 9Y4 is 7.699 EUR with a low forecast of 5.326 EUR and a high forecast of 9.445 EUR.

What is the Revenue forecast for Ryvu Therapeutics SA?
Projected CAGR
22%

Over the last 12 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 8 years is 22%.

What is the Gross Profit forecast for Ryvu Therapeutics SA?
Projected CAGR
-29%

Over the last 12 years, the compound annual growth rate for Gross Profit has been 23%. The projected CAGR for the next 3 years is -29%.

Back to Top
ALPHA SPREAD
Follow us
Join 355,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett